Genome-based diagnostics: demonstrating clinical utility in oncology : workshop summary
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch Tagungsbericht E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
<<The>> National Academies Press
[2013]
|
| Schlagworte: | |
| Online-Zugang: | TUM01 Volltext |
| Beschreibung: | 1 Online-Ressource (xix, 101 Seiten) |
| ISBN: | 9780309269605 0309269601 9780309269599 0309269598 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042796159 | ||
| 003 | DE-604 | ||
| 005 | 20160609 | ||
| 006 | a |||| 10||| | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 150902s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9780309269605 |c Online |9 978-0-309-26960-5 | ||
| 020 | |a 0309269601 |c Online |9 0-309-26960-1 | ||
| 020 | |a 9780309269599 |c print |9 978-0-309-26959-9 | ||
| 020 | |a 0309269598 |c print |9 0-309-26959-8 | ||
| 035 | |a (ZDB-4-NLEBK)867919 | ||
| 035 | |a (OCoLC)870331185 | ||
| 035 | |a (DE-599)BVBBV042796159 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91 | ||
| 082 | 0 | |a 616.99/4075 |2 23 | |
| 245 | 1 | 0 | |a Genome-based diagnostics |b demonstrating clinical utility in oncology : workshop summary |c Adam C. Berger and Steve Olson, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies and Center for Medical Technology Policy |
| 264 | 1 | |a Washington, D.C. |b <<The>> National Academies Press |c [2013] | |
| 300 | |a 1 Online-Ressource (xix, 101 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 505 | 8 | |a "Genome-Based Diagnostics: Demonstrating Clinical Utility in Oncology is the summary of a workshop convened in May 2012 by the Roundtable on Translating Genomic-Based Research for Health and the Center for Medical Technology Policy of the Institute of Medicine to foster the identified need for further sustained dialogue between stakeholders regarding the clinical utility of molecular diagnostics. The workshop brought together a wide range of stakeholders, including patients, health care providers, policy makers, payers, diagnostic test developers, researchers, and guideline developers, to identify the challenges and opportunities in advancing the development and use of molecular diagnostic tests designed to guide the treatment and management of patients with cancer. The sequencing of the human genome has greatly accelerated the process of linking specific genetic variants with disease. These findings have yielded a rapidly increasing number of molecular diagnostic tests designed to guide disease treatment and management. Many of these tests are aimed at determining the best treatments for specific forms of cancer, making oncology a valuable testing ground for the use of molecular diagnostic tests in medicine in general. Nevertheless, many questions surround the clinical value of molecular diagnostic tests, and their acceptance by clinicians, payers, and patients has been unpredictable. A major limiting factor for the use of these tests has been the lack of clear evidence of clinical utility. Genome-Based Diagnostics assesses the evidentiary requirements for clinical utility of molecular diagnostics used to guide treatment decisions for patients with cancer; discusses methodologies related to demonstrating these evidentiary requirements that meet the needs of all stakeholders; and considers innovative, sustainable research collaborations for generating evidence of clinical utility involving multiple stakeholders"--Publisher's description | |
| 505 | 8 | |a Includes bibliographical references | |
| 505 | 8 | |a Introduction -- Setting the context -- Perspectives from stakeholders -- Tools for generating and synthesizing evidence -- Advancing molecular diagnostics for oncology | |
| 650 | 4 | |a Neoplasms / diagnosis / Congresses | |
| 650 | 4 | |a Molecular Diagnostic Techniques / Congresses | |
| 650 | 7 | |a Cancer / Molecular diagnosis |2 fast | |
| 650 | 7 | |a Molecular diagnosis |2 fast | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Clinical Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Diseases |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Evidence-Based Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Internal Medicine |2 bisacsh | |
| 650 | 4 | |a Evidenz-basierte Medizin | |
| 650 | 4 | |a Innere Medizin | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Molecular diagnosis |v Congresses | |
| 650 | 4 | |a Cancer |x Molecular diagnosis |v Congresses | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 24.05.2012 |z Washington, DC |2 gnd-content | |
| 700 | 1 | |a Berger, Adam C. |0 (DE-588)107101160X |4 com | |
| 700 | 1 | |a Olson, Steve |4 com | |
| 710 | 2 | |a Roundtable on Translating Genomic Based Research for Health (Washington, DC) |0 (DE-588)16152347-X |4 orm | |
| 711 | 2 | |a Evidence for Clinical Utility of Molecular Diagnostics in Oncology (Veranstaltung) |d 2012 |c Washington, DC |j Sonstige |0 (DE-588)1103141503 |4 oth | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867919 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028225931 | ||
| 966 | e | |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867919 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCOMED_gekauft |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175029159591936 |
|---|---|
| any_adam_object | |
| author2 | Berger, Adam C. Olson, Steve |
| author2_role | com com |
| author2_variant | a c b ac acb s o so |
| author_GND | (DE-588)107101160X |
| author_facet | Berger, Adam C. Olson, Steve |
| building | Verbundindex |
| bvnumber | BV042796159 |
| collection | ZDB-4-EBA ZDB-4-NLEBK |
| contents | "Genome-Based Diagnostics: Demonstrating Clinical Utility in Oncology is the summary of a workshop convened in May 2012 by the Roundtable on Translating Genomic-Based Research for Health and the Center for Medical Technology Policy of the Institute of Medicine to foster the identified need for further sustained dialogue between stakeholders regarding the clinical utility of molecular diagnostics. The workshop brought together a wide range of stakeholders, including patients, health care providers, policy makers, payers, diagnostic test developers, researchers, and guideline developers, to identify the challenges and opportunities in advancing the development and use of molecular diagnostic tests designed to guide the treatment and management of patients with cancer. The sequencing of the human genome has greatly accelerated the process of linking specific genetic variants with disease. These findings have yielded a rapidly increasing number of molecular diagnostic tests designed to guide disease treatment and management. Many of these tests are aimed at determining the best treatments for specific forms of cancer, making oncology a valuable testing ground for the use of molecular diagnostic tests in medicine in general. Nevertheless, many questions surround the clinical value of molecular diagnostic tests, and their acceptance by clinicians, payers, and patients has been unpredictable. A major limiting factor for the use of these tests has been the lack of clear evidence of clinical utility. Genome-Based Diagnostics assesses the evidentiary requirements for clinical utility of molecular diagnostics used to guide treatment decisions for patients with cancer; discusses methodologies related to demonstrating these evidentiary requirements that meet the needs of all stakeholders; and considers innovative, sustainable research collaborations for generating evidence of clinical utility involving multiple stakeholders"--Publisher's description Includes bibliographical references Introduction -- Setting the context -- Perspectives from stakeholders -- Tools for generating and synthesizing evidence -- Advancing molecular diagnostics for oncology |
| ctrlnum | (ZDB-4-NLEBK)867919 (OCoLC)870331185 (DE-599)BVBBV042796159 |
| dewey-full | 616.99/4075 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4075 |
| dewey-search | 616.99/4075 |
| dewey-sort | 3616.99 44075 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic Conference Proceeding eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05009nmm a2200625zc 4500</leader><controlfield tag="001">BV042796159</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160609 </controlfield><controlfield tag="006">a |||| 10||| </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">150902s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309269605</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-309-26960-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309269601</subfield><subfield code="c">Online</subfield><subfield code="9">0-309-26960-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309269599</subfield><subfield code="c">print</subfield><subfield code="9">978-0-309-26959-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309269598</subfield><subfield code="c">print</subfield><subfield code="9">0-309-26959-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)867919</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)870331185</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042796159</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4075</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Genome-based diagnostics</subfield><subfield code="b">demonstrating clinical utility in oncology : workshop summary</subfield><subfield code="c">Adam C. Berger and Steve Olson, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies and Center for Medical Technology Policy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b"><<The>> National Academies Press</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xix, 101 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">"Genome-Based Diagnostics: Demonstrating Clinical Utility in Oncology is the summary of a workshop convened in May 2012 by the Roundtable on Translating Genomic-Based Research for Health and the Center for Medical Technology Policy of the Institute of Medicine to foster the identified need for further sustained dialogue between stakeholders regarding the clinical utility of molecular diagnostics. The workshop brought together a wide range of stakeholders, including patients, health care providers, policy makers, payers, diagnostic test developers, researchers, and guideline developers, to identify the challenges and opportunities in advancing the development and use of molecular diagnostic tests designed to guide the treatment and management of patients with cancer. The sequencing of the human genome has greatly accelerated the process of linking specific genetic variants with disease. These findings have yielded a rapidly increasing number of molecular diagnostic tests designed to guide disease treatment and management. Many of these tests are aimed at determining the best treatments for specific forms of cancer, making oncology a valuable testing ground for the use of molecular diagnostic tests in medicine in general. Nevertheless, many questions surround the clinical value of molecular diagnostic tests, and their acceptance by clinicians, payers, and patients has been unpredictable. A major limiting factor for the use of these tests has been the lack of clear evidence of clinical utility. Genome-Based Diagnostics assesses the evidentiary requirements for clinical utility of molecular diagnostics used to guide treatment decisions for patients with cancer; discusses methodologies related to demonstrating these evidentiary requirements that meet the needs of all stakeholders; and considers innovative, sustainable research collaborations for generating evidence of clinical utility involving multiple stakeholders"--Publisher's description</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Introduction -- Setting the context -- Perspectives from stakeholders -- Tools for generating and synthesizing evidence -- Advancing molecular diagnostics for oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms / diagnosis / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular Diagnostic Techniques / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer / Molecular diagnosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular diagnosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Evidence-Based Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Internal Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Evidenz-basierte Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Innere Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular diagnosis</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Molecular diagnosis</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">24.05.2012</subfield><subfield code="z">Washington, DC</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, Adam C.</subfield><subfield code="0">(DE-588)107101160X</subfield><subfield code="4">com</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olson, Steve</subfield><subfield code="4">com</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Roundtable on Translating Genomic Based Research for Health (Washington, DC)</subfield><subfield code="0">(DE-588)16152347-X</subfield><subfield code="4">orm</subfield></datafield><datafield tag="711" ind1="2" ind2=" "><subfield code="a">Evidence for Clinical Utility of Molecular Diagnostics in Oncology (Veranstaltung)</subfield><subfield code="d">2012</subfield><subfield code="c">Washington, DC</subfield><subfield code="j">Sonstige</subfield><subfield code="0">(DE-588)1103141503</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867919</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028225931</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867919</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCOMED_gekauft</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content (DE-588)1071861417 Konferenzschrift 24.05.2012 Washington, DC gnd-content |
| genre_facet | Konferenzschrift Konferenzschrift 24.05.2012 Washington, DC |
| id | DE-604.BV042796159 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:09:47Z |
| institution | BVB |
| institution_GND | (DE-588)16152347-X (DE-588)1103141503 |
| isbn | 9780309269605 0309269601 9780309269599 0309269598 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028225931 |
| oclc_num | 870331185 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (xix, 101 Seiten) |
| psigel | ZDB-4-EBA ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCOMED_gekauft |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | <<The>> National Academies Press |
| record_format | marc |
| spelling | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary Adam C. Berger and Steve Olson, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies and Center for Medical Technology Policy Washington, D.C. <<The>> National Academies Press [2013] 1 Online-Ressource (xix, 101 Seiten) txt rdacontent c rdamedia cr rdacarrier "Genome-Based Diagnostics: Demonstrating Clinical Utility in Oncology is the summary of a workshop convened in May 2012 by the Roundtable on Translating Genomic-Based Research for Health and the Center for Medical Technology Policy of the Institute of Medicine to foster the identified need for further sustained dialogue between stakeholders regarding the clinical utility of molecular diagnostics. The workshop brought together a wide range of stakeholders, including patients, health care providers, policy makers, payers, diagnostic test developers, researchers, and guideline developers, to identify the challenges and opportunities in advancing the development and use of molecular diagnostic tests designed to guide the treatment and management of patients with cancer. The sequencing of the human genome has greatly accelerated the process of linking specific genetic variants with disease. These findings have yielded a rapidly increasing number of molecular diagnostic tests designed to guide disease treatment and management. Many of these tests are aimed at determining the best treatments for specific forms of cancer, making oncology a valuable testing ground for the use of molecular diagnostic tests in medicine in general. Nevertheless, many questions surround the clinical value of molecular diagnostic tests, and their acceptance by clinicians, payers, and patients has been unpredictable. A major limiting factor for the use of these tests has been the lack of clear evidence of clinical utility. Genome-Based Diagnostics assesses the evidentiary requirements for clinical utility of molecular diagnostics used to guide treatment decisions for patients with cancer; discusses methodologies related to demonstrating these evidentiary requirements that meet the needs of all stakeholders; and considers innovative, sustainable research collaborations for generating evidence of clinical utility involving multiple stakeholders"--Publisher's description Includes bibliographical references Introduction -- Setting the context -- Perspectives from stakeholders -- Tools for generating and synthesizing evidence -- Advancing molecular diagnostics for oncology Neoplasms / diagnosis / Congresses Molecular Diagnostic Techniques / Congresses Cancer / Molecular diagnosis fast Molecular diagnosis fast HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Evidenz-basierte Medizin Innere Medizin Medizin Molecular diagnosis Congresses Cancer Molecular diagnosis Congresses (DE-588)1071861417 Konferenzschrift gnd-content (DE-588)1071861417 Konferenzschrift 24.05.2012 Washington, DC gnd-content Berger, Adam C. (DE-588)107101160X com Olson, Steve com Roundtable on Translating Genomic Based Research for Health (Washington, DC) (DE-588)16152347-X orm Evidence for Clinical Utility of Molecular Diagnostics in Oncology (Veranstaltung) 2012 Washington, DC Sonstige (DE-588)1103141503 oth http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867919 Aggregator Volltext |
| spellingShingle | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary "Genome-Based Diagnostics: Demonstrating Clinical Utility in Oncology is the summary of a workshop convened in May 2012 by the Roundtable on Translating Genomic-Based Research for Health and the Center for Medical Technology Policy of the Institute of Medicine to foster the identified need for further sustained dialogue between stakeholders regarding the clinical utility of molecular diagnostics. The workshop brought together a wide range of stakeholders, including patients, health care providers, policy makers, payers, diagnostic test developers, researchers, and guideline developers, to identify the challenges and opportunities in advancing the development and use of molecular diagnostic tests designed to guide the treatment and management of patients with cancer. The sequencing of the human genome has greatly accelerated the process of linking specific genetic variants with disease. These findings have yielded a rapidly increasing number of molecular diagnostic tests designed to guide disease treatment and management. Many of these tests are aimed at determining the best treatments for specific forms of cancer, making oncology a valuable testing ground for the use of molecular diagnostic tests in medicine in general. Nevertheless, many questions surround the clinical value of molecular diagnostic tests, and their acceptance by clinicians, payers, and patients has been unpredictable. A major limiting factor for the use of these tests has been the lack of clear evidence of clinical utility. Genome-Based Diagnostics assesses the evidentiary requirements for clinical utility of molecular diagnostics used to guide treatment decisions for patients with cancer; discusses methodologies related to demonstrating these evidentiary requirements that meet the needs of all stakeholders; and considers innovative, sustainable research collaborations for generating evidence of clinical utility involving multiple stakeholders"--Publisher's description Includes bibliographical references Introduction -- Setting the context -- Perspectives from stakeholders -- Tools for generating and synthesizing evidence -- Advancing molecular diagnostics for oncology Neoplasms / diagnosis / Congresses Molecular Diagnostic Techniques / Congresses Cancer / Molecular diagnosis fast Molecular diagnosis fast HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Evidenz-basierte Medizin Innere Medizin Medizin Molecular diagnosis Congresses Cancer Molecular diagnosis Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary |
| title_auth | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary |
| title_exact_search | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary |
| title_full | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary Adam C. Berger and Steve Olson, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies and Center for Medical Technology Policy |
| title_fullStr | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary Adam C. Berger and Steve Olson, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies and Center for Medical Technology Policy |
| title_full_unstemmed | Genome-based diagnostics demonstrating clinical utility in oncology : workshop summary Adam C. Berger and Steve Olson, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies and Center for Medical Technology Policy |
| title_short | Genome-based diagnostics |
| title_sort | genome based diagnostics demonstrating clinical utility in oncology workshop summary |
| title_sub | demonstrating clinical utility in oncology : workshop summary |
| topic | Neoplasms / diagnosis / Congresses Molecular Diagnostic Techniques / Congresses Cancer / Molecular diagnosis fast Molecular diagnosis fast HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Evidenz-basierte Medizin Innere Medizin Medizin Molecular diagnosis Congresses Cancer Molecular diagnosis Congresses |
| topic_facet | Neoplasms / diagnosis / Congresses Molecular Diagnostic Techniques / Congresses Cancer / Molecular diagnosis Molecular diagnosis HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine Evidenz-basierte Medizin Innere Medizin Medizin Molecular diagnosis Congresses Cancer Molecular diagnosis Congresses Konferenzschrift Konferenzschrift 24.05.2012 Washington, DC |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867919 |
| work_keys_str_mv | AT bergeradamc genomebaseddiagnosticsdemonstratingclinicalutilityinoncologyworkshopsummary AT olsonsteve genomebaseddiagnosticsdemonstratingclinicalutilityinoncologyworkshopsummary AT roundtableontranslatinggenomicbasedresearchforhealthwashingtondc genomebaseddiagnosticsdemonstratingclinicalutilityinoncologyworkshopsummary AT evidenceforclinicalutilityofmoleculardiagnosticsinoncologyveranstaltungwashingtondc genomebaseddiagnosticsdemonstratingclinicalutilityinoncologyworkshopsummary |